Characteristics and resistance of tachyplesin-I resistance in Pseudomonas aeruginosa
Author:
  • Article
  • | |
  • Metrics
  • |
  • Reference [23]
  • |
  • Related
  • | | |
  • Comments
    Abstract:

    [Objective] To explore the safety of tachyplesin I as an antibacterial drug for wide clinical application, we induced Pseudomonas aeruginosa resistance to tachyplesin I and studied the preliminary resistance mechanisms, which may provide theoretical basis for the widely application of tachyplesin-I.[Methods] First, we induced P. aeruginosa resistance to tachyplesin I using continuously increasing concentration selection pressure and monitored bacterial resistance. Second, we studied the stability, cross-resistance and cost of resistance of resistant strain. Last, we investigated the potential role of extracellular proteases, extracellular polysaccharide content and biofilm formation in the resistance mechanism.[Results] After more than 30 serial transfers in P. aeruginosa ATCC27853 under increasing concentrations of tachyplesin I selection, the MICvalues for P. aeruginosa was gradually increased, whereas high resistance to tachyplesin I was produced until 80 serial transfers. P. aeruginosa ATCC27853 showed resistance to tachyplesin I under long-term, continuously increasing concentration selection pressure. Cross-resistances between tachyplesin I, amikacin and other antimicrobial peptides (pexiganan, tachyplesin Ⅲ, and polyphemusin I) were observed in resistant mutant. Our resistant strain displayed a substantial cost of resistance mainly in the form of a much longer lag phase in the absence of tachyplesin I in P. aeruginosa, whereas in the presence of tachyplesin I, resistant strain had a shorter lag phase and greater growth rate. The resistant strain P. aeruginosa ATCC27853-88-2 exhibited increased levels of extracellular proteolytic activity and reduced the antimicrobial activity of tachyplesin I. Under the same conditions, extracellular polysaccharide content of the resistant strain was higher, more easily to form biofilm than the original strain.[Conclusion] We demonstrate that long-term continuous exposure to high concentrations of tachyplesin I can induce resistance in P. aeruginosa ATCC27853 and the potential involvement of extracellular protease and biofilm formation in mediating this resistance.

    Reference
    [1] Anaya-López JL, López-Meza JE, Ochoa-Zarzosa A. Bacterial resistance to cationic antimicrobial peptides. Critical Reviews in Microbiology, 2013, 39(2):180-195, doi:10.3109/1040841X.2012.699025.
    [2] Cai Y, Chai D, Wang R, Liang BB, Bai N. Colistin resistance of Acinetobacter baumannii:clinical reports, mechanisms and antimicrobial strategies. Journal of Antimicrobial Chemotherapy, 2012, 67(7):1607-1615.
    [3] Perron GG, Zasloff M, Bell G. Experimental evolution of resistance to an antimicrobial peptide. Proceedings of the Royal Society B:Biological Sciences, 2006, 273(1583):251-256.
    [4] Peschel A, Sahl HG. The co-evolution of host cationic antimicrobial peptides and microbial resistance. Nature Reviews Microbiology, 2006, 4(7):529-536.
    [5] Hong J, Guan WT, Jin G, Zhao HY, Jiang XH, Dai JG. Mechanism of tachyplesin I injury to bacterial membranes and intracellular enzymes, determined by laser confocal scanning microscopy and flow cytometry. Microbiological Research, 2015, 170:69-77.
    [6] Dai JG, Xie HW, Jin G, Wang WG, Zhang Y, Guo Y. Preliminary study on high-level expression of tandem-arranged tachyplesin-encoding gene in Bacillus subtilis Wb800 and its antibacterial activity. Marine Biotechnology, 2009, 11(1):109-117.
    [7] 田颖. 鲎素抗菌肽对海兰褐蛋鸡产蛋后期蛋品质及子宫CaBP-D28k mRNA表达量影响的研究. 吉林大学硕士学位论文, 2016.
    [8] Zhang Y, Feng X, Han D, Tie KY, Zhang QY, Yu X, Han WY. Therapeutic effect of genetic engineering tachyplesin I on Staphylococcus aureus infection in mice. Chinese Journal of Veterinary Science, 2017, 37(4):682-685, 691. (in Chinese)张洋, 冯新, 韩东, 铁鲲源, 张楸杨, 于曦, 韩文瑜. 基因工程鲎素对金黄色葡萄球菌小鼠感染模型治疗效果. 中国兽医学报, 2017, 37(4):682-685, 691.
    [9] Gao Y, Zhao HL, Feng X, Zhai RD, Zhu S, Du CT, Sun CJ, Lei LC. Expression of recombinant human lysozyme-tachyplesin I (hLYZ-TP I) in Pichia pastoris and analysis of antibacterial activity. Biomedical and Environmental Sciences, 2013, 26(4):319-322.
    [10] 曹原. 基因工程鲎素Tachyplesin I的工业化生产及其皮肤抗菌凝胶的研制. 吉林大学硕士学位论文, 2017.
    [11] Hong J, Dai JG, Guan WT, Jin G, Huang ZL, Zhang LJ, Zhang Y. Tachyplesin I induce drug resistance in bacteria in vitro. Journal of Animal and Veterinary Advances, 2012, 11(7):939-945.
    [12] Hong J, Hu JY, Ke F. Experimental induction of bacterial resistance to the antimicrobial peptide tachyplesin I and investigation of the resistance mechanisms. Antimicrobial Agents and Chemotherapy, 2016, 60(10):6067-6075.
    [13] Li M, Lai YP, Villaruz AE, Cha DJ, Sturdevant DE, Otto M. Gram-positive three-component antimicrobial peptide-sensing system. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104(22):9469-9474.
    [14] Lai YP, Villaruz AE, Li M, Cha DJ, Sturdevant DE, Otto M. The human anionic antimicrobial peptide dermcidin induces proteolytic defence mechanisms in staphylococci. Molecular Microbiology, 2007, 63(2):497-506.
    [15] Dean SN, Bishop BM, van Hoek ML. Susceptibility of Pseudomonas aeruginosa biofilm to alpha-helical peptides:D-enantiomer of LL-37. Frontiers in Microbiology, 2011, 2:128.
    [16] 曾祥萍. AL-1单用及联合用药对铜绿假单胞菌生物膜形成的抑制作用及其作用机理研究. 暨南大学硕士学位论文, 2011.
    [17] Mehla J, Sood SK. Substantiation in Enterococcus faecalis of dose-dependent resistance and cross-resistance to pore-forming antimicrobial peptides by use of a polydiacetylene-based colorimetric assay. Applied and Environmental Microbiology, 2011, 77(3):786-793.
    [18] Habets MGJL, Brockhurst MA. Therapeutic antimicrobial peptides may compromise natural immunity. Biology Letters, 2012, 8(3):416-418.
    [19] Lofton H, Pränting M, Thulin E, Andersson DI. Mechanisms and fitness costs of resistance to antimicrobial peptides LL-37, CNY100HL and wheat germ histones. PLoS One, 2013, 8(7):e68875.
    [20] Gruenheid S, Le Moual H. Resistance to antimicrobial peptides in Gram-negative bacteria. FEMS Microbiology Letters, 2012, 330(2):81-89.
    [21] Nuri R, Shprung T, Shai Y. Defensive remodeling:How bacterial surface properties and biofilm formation promote resistance to antimicrobial peptides. Biochimica et Biophysica Acta (BBA)-Biomembranes, 2015, 1848(11):3089-3100.
    [22] Sieprawska-Lupa M, Mydel P, Krawczyk K, Wójcik K, Puklo M, Lupa B, Suder P, Silberring J, Reed M, Pohl J, Shafer W, McAleese F, Foster T, Travis J, Potempa J. Degradation of human antimicrobial peptide LL-37 by Staphylococcus aureus-derived proteinases. Antimicrobial Agents and Chemotherapy, 2004, 48(12):4673-4679.
    [23] Fuente-Núñez CDL, Korolik V, Bains M, Nguyen U, Breidenstein EBM, Horsman S, Lewenza S, Burrows L, Hancock REW. Inhibition of bacterial biofilm formation and swarming motility by a small synthetic cationic peptide. Antimicrobial Agents and Chemotherapy, 2012, 56(5):2696-2704.
    Related
    Cited by
Get Citation

Jun Hong, Jianye Hu, Kun Liu, Chaohua Wang, Chunyun Zhou, Kunmin Yan, Shuangshuang Gao. Characteristics and resistance of tachyplesin-I resistance in Pseudomonas aeruginosa. [J]. Acta Microbiologica Sinica, 2018, 58(9): 1593-1604

Copy
Share
Article Metrics
  • Abstract:
  • PDF:
  • HTML:
  • Cited by:
History
  • Received:November 06,2017
  • Revised:December 26,2017
  • Online: August 27,2018
Article QR Code